Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Though deal value is down, volume is stable (with biopharma deals +17% vs. 2023), but average deal size dropped, as companies ...

Director / Senior Director Antibody Conjugate Development Position Overview: Argo Biopharma is a Biotech focusing on developing siRNA-based therapeutics to address unmet medical needs. We are ...

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $17.00. Discover outperforming stocks ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $11.00. The company’s shares closed ...

Tanvex BioPharma, Inc. ("Tanvex"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion ...

and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of ...

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play ...